iwfal, Agree Geron not good re disseminating info witness 8 years of phase I CLL data and solid tumor data never really discussed in any detail. Re your points: PV has never been put forward as an indication, only that there may be commonality in the precursor myeloid cell with ET. Therefore maybe not so very different even though eventual different differentiated cell lines. Agree Geron's data so far only relevant to ET at ASH but PV of interest because of potential effect on same myeloid precursor cell. Holy grail appears to be MF. Found an interesting article that you and Don Shimoda might be interested in: JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths by Dr. Ayalew Tefferi of Mayo. Dr. Tefferi emphasizes the issue of the importance of "disease modification" via future, more effective drugs and absence thereof with current therapies. Lots of overlap in language with Geron's description of the findings with imetelstat and ET. Worth a read. I am not defending Geron who have spent 20 years and a lot of money only to abandon their stem cell program and put it where? BTX who basically has no money. Their solid tumor program is a disaster. That said it looks to me like the reason they changed course was the potential for disease modification in myeloproliferative neoplasms, so far as I can see this would represent a unique approach the this set of diseases. Regards, bp
